Hepatitis coinfection


HIV/HCV. The PROBE-C Study
An emerging problem worldwide is the epidemics of acute hepatitis C in HIV-positive men who have sex with men (MSM), firstly described in London in the beginning of 2000, and subsequently reported by several investigators in different countries. NEAT initial plan was to conduct a multinational clinical trial to test efficacy and safety of different treatments for this condition. However, two main considerations led NEAT General Assembly to modify the plan: the high costs of this study and the several controversies existing in the field. Indeed, the natural history of the disease and its actual incidence are still unknown. Therefore, a “hepatitis group” has been set up within NEAT that includes the major experts in the field and contributors to > 90% of published cases on acute HCV infection. This group will work at establishing a cohort of patients for the PRospective OBservational Evaluation (PROBE) study on the natural history and treatment of acute HCV in HIV positive individuals in Europe. Besides collecting unique information on this new epidemics, PROBE will provide a clinical platform to explore safety and efficacy of different treatment approaches.

List of partners involved in the study

AP-HP, Hôpital La Pitié Salpétrière, Paris, France Brigitte Autran
Stephanie Dominguez
Marguerite Guiguet
Christine Katlama
Marc-Antoine Valantin
Hospital Carlos III, Madrid, Spain Francisco Blanco
Vincent Soriano
Fundacio Lluita contra la SIDA, Barcelona, Spain Bonaventura Clotet
Cristina Tural
Saint Pierre University Hospital, Brussels, Belgium Nathan Clumeck
Università degli studi di Milano, Italy Massimo Galli
European AIDS Treatment Group, Brussels, Belgium Diego Garcia
Hospital Clinic i Provincial de Barcelona, Spain Jose Gatell
Jose Mallola
University College London, United Kingdom Richard Gilson
Wojewodzki Szpital Zakazny, Warsaw, Poland Andrzej Horban
University of Bonn, Germany Guido Lüchters
Jürgen K. Rockstroh
Martin Vogel
Christoph Boesecke
Svetlana Hass
Medical School Hannover, Germany Dirk Meyer-Olson
Reinhold Schmidt
St. Stephens AIDS Trust / Chelsea Westminster Hospital, London, United Kingdom Mark Nelson
Emma Page
Centre of excellence for Health, immunity and Infections, CHIP, Denmark Lars Peters
Università degli Studi di Brescia Institute of Infectious and tropical diseases, Italy Massimo Puoti
Academisch Medisch Centrum, Amsterdam, The Netherlands Peter Reiss
University of Frankfurt / Main, Germany Christoph Stephan
Markus Bickel
Pavel Khaykin